We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+0.5%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$3.29B
AUM Growth
-$103M
Cap. Flow
+$24.5M
Cap. Flow %
0.75%
Top 10 Hldgs %
70.15%
Holding
85
New
9
Increased
10
Reduced
4
Closed
19

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$56.5M
2
ACET icon
Adicet Bio
ACET
+$55.5M
3
ZYME icon
Zymeworks
ZYME
+$53.2M
4
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
+$36.9M
5
DYN icon
Dyne Therapeutics
DYN
+$26.9M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$70.9M
2
GOSS icon
Gossamer Bio
GOSS
+$49.8M
3
RNAM
Avidity Biosciences
RNAM
+$47.3M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$39.1M
5
DSGN icon
Design Therapeutics
DSGN
+$22.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.78%
2 Financials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALGS icon
51
Aligos Therapeutics
ALGS
$26.3M
$3.76M 0.11%
157,934
– –
ABEO icon
52
Abeona Therapeutics
ABEO
$343M
$3.35M 0.1%
+1,086,956
New +$4.07M
SURF
53
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$3.22M 0.1%
3,924,713
– –
ERAS icon
54
Erasca
ERAS
$6.3B
$2.92M 0.09%
678,441
– –
HOOK
55
DELISTED
HOOKIPA Pharma
HOOK
$2M 0.06%
247,349
-252,651
-51% -$2.74M
EUCR
56
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
$2M 0.06%
200,000
– –
NUVB.WS
57
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$1.85M 0.06%
963,333
– –
ARYD
58
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$1.51M 0.05%
150,000
– –
TPST icon
59
Tempest Therapeutics
TPST
$13.9M
$1.19M 0.04%
79,328
– –
ITOS
60
DELISTED
iTeos Therapeutics
ITOS
$791K 0.02%
40,480
– –
NAMSW icon
61
NewAmsterdam Pharma Warrant
NAMSW
$76.2M
$727K 0.02%
+66,665
New +$54.9K
EUCRW
62
DELISTED
Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
$666K 0.02%
66,666
– –
KRON
63
DELISTED
Kronos Bio
KRON
$529K 0.02%
326,780
– –
BDTX icon
64
Black Diamond Therapeutics
BDTX
$101M
$508K 0.02%
+282,131
New +$508K
CMAXW
65
DELISTED
CareMax, Inc. Warrant
CMAXW
$365K 0.01%
100,000
– –
SRZNW icon
66
Surrozen Inc Warrant
SRZNW
$75.6K
$38.8K ﹤0.01%
66,665
– –
ARGX icon
67
argenx
ARGX
$54.6B
– –
-17,527
Closed -$6.19M
ASND icon
68
Ascendis Pharma A/S
ASND
$16.7B
– –
-27,208
Closed -$2.81M
DSGN icon
69
CALL
Design Therapeutics
DSGN
$741M
– –
-63,400
Closed -$1.06M
GOSS icon
70
Gossamer Bio
GOSS
$100M
– –
-4,160,887
Closed -$49.8M
NUVL
71
DELISTED
Nuvalent
NUVL
– –
-40,970
Closed -$796K
RNAM
72
DELISTED
Avidity Biosciences
RNAM
– –
-2,899,285
Closed -$47.3M
KNTE
73
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
– –
-175,000
Closed -$2.09M
MRTX
74
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-1,015,572
Closed -$70.9M
SGEN
75
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-285,793
Closed -$39.1M
1 2
3
4

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q4 2022 Portfolio in Review

As of Q4 2022, EcoR1 Capital held 85 positions worth $3.29B, down 3% from $3.39B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

EcoR1 Capital's Q4 2022 filing shows 9 new, 10 increased, 4 reduced and 19 closed positions. Its largest new stake was Adicet Bio: 222,544 shares worth $31.8M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $70.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

  • EcoR1 Capital's largest Q4 2022 buy was Adicet Bio: 222,544 shares worth $31.8M.
  • EcoR1 Capital added most to Revolution Medicines in Q4 2022, an estimated $56.5M increase.
  • EcoR1 Capital's biggest Q4 2022 reduction was Design Therapeutics, cutting an estimated $22.1M.
  • EcoR1 Capital fully exited Mirati Therapeutics, Inc. Common Stock in Q4 2022, selling an estimated $70.9M.
  • EcoR1 Capital's ten largest holdings make up 70% of its $3.29B portfolio in Q4 2022.
  • EcoR1 Capital opened 9 new positions and closed 19 in Q4 2022.
  • EcoR1 Capital's portfolio value fell 3% quarter-over-quarter to $3.29B.

Based on EcoR1 Capital's 13F filing for Q4 2022, filed 14 Feb 2023.